Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 81 of 81 drug-target rows in SSL view, for TSG = MSH6.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
olaparib MSH6 PARP1 1
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MSH6 DHFR 2
alvocidib, paclitaxel MSH6 CDK9 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 MSH6 DHFR 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging MSH6 ACE2 2
biospecimen collection, computed tomography, pemetrexed MSH6 DHFR 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab MSH6 DHFR 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide MSH6 DHFR 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib MSH6 DHFR 2
laboratory biomarker analysis, oxaliplatin, pralatrexate MSH6 DHFR 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab MSH6 DHFR 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed MSH6 DHFR 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a MSH6 DHFR 2
motexafin gadolinium, radiation therapy MSH6 RRM2 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine MSH6 DHFR 2
pemetrexed, bevacizumab MSH6 DHFR 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography MSH6 DHFR 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed MSH6 DHFR 2
tislelizumab, pemetrexed MSH6 DHFR 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy MSH6 DHFR 2
pemetrexed MSH6 DHFR 7
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy (imrt), temozolomide, chloroquine, tumor treating fields therapy (ttf) MSH6 ACE2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide MSH6 RRM2 1
alvocidib, docetaxel MSH6 CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis MSH6 CDK9 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel MSH6 DHFR 1
binimetinib, hydroxychloroquine MSH6 ACE2 1
can04, cisplatin, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed MSH6 DHFR 1
certolizumab, cisplatin, pemetrexed MSH6 DHFR 1
chemotherapy, cladribine, radiation therapy MSH6 RRM2 1
chloroquine MSH6 ACE2 1
chloroquine, radiotherapy, temozolomide MSH6 ACE2 1
cisplatin, methotrexate, vinorelbine ditartrate, adjuvant therapy, conventional surgery, neoadjuvant therapy, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy MSH6 DHFR 1
cobimetinib, hydroxychloroquine, atezolizumab MSH6 ACE2 1
conventional surgery, 3-dimensional conformal radiation therapy, stereotactic radiosurgery, motexafin gadolinium, magnetic resonance imaging, spectroscopy MSH6 RRM2 1
cryoablation, pembrolizumab, pemetrexed, carboplatin MSH6 DHFR 1
epacadostat, pembrolizumab, oxaliplatin, leucovorin, 5-fluorouracil, gemcitabine, nab-paclitaxel, carboplatin, paclitaxel, pemetrexed, cyclophosphamide, carboplatin, cisplatin, 5-fluorouracil, investigator's choice of platinum agent MSH6 DHFR 1
erlotinib, pemetrexed, cisplatin, erlotinib MSH6 DHFR 1
farletuzumab, placebo, carboplatin, paclitaxel, pemetrexed, cisplatin MSH6 DHFR 1
gemcitabine, abraxane, hydroxychloroquine MSH6 ACE2 1
gemcitabine, hydroxychloroquine, nab-paclitaxel, paricalcitol MSH6 ACE2 1
gen1042, pembrolizumab, cisplatin, carboplatin, 5-fu, gemcitabine, nab paclitaxel, pemetrexed, paclitaxel MSH6 DHFR 1
hydroxychloroquine, gemcitabine MSH6 ACE2 1
hydroxychloroquine, radiotherapy MSH6 ACE2 1
hydroxychloroquine, temozolomide, pharmacological study, radiation MSH6 ACE2 1
imexon, gemcitabine MSH6 RRM2 1
leucovorin calcium, methotrexate MSH6 DHFR 1
methotrexate, pharmacological study MSH6 DHFR 1
mopp regimen, leucovorin calcium, mechlorethamine hydrochloride, methotrexate, prednisone, procarbazine hydrochloride, vincristine sulfate, conventional surgery MSH6 DHFR 1
motexafin gadolinium MSH6 RRM2 1
motexafin gadolinium, magnetic resonance imaging, surgical procedure MSH6 RRM2 1
paclitaxel protein bound, gemcitabine, cisplatin, hydroxychloroquine MSH6 ACE2 1
paclitaxel, pemetrexed, 5fluorouracil, carboplatin, pembrolizumab MSH6 DHFR 1
paricalcitol, hydroxychloroquine, losartan, neoadjuvant therapy and surgery only (control) MSH6 ACE2 1
pemetrexed, cetuximab, cisplatin, folic acid, vitamin b12 MSH6 DHFR 1
pemetrexed, cisplatin MSH6 DHFR 1
pf-07934040, gemcitabine, nab-paclitaxel, cetuximab, fluorouracil, oxaliplatin, leucovorin, bevacizumab, pembrolizumab, pemetrexed, cisplatin, paclitaxel, carboplatin MSH6 DHFR 1
pf-07985045, gemcitabine, nab-paclitaxel, cetuximab, fluorouracil, oxaliplatin, leucovorin, bevacizumab, pembrolizumab, sasanlimab, pemetrexed, cisplatin, paclitaxel, carboplatin, pf-07284892 MSH6 DHFR 1
tacrolimus, methotrexate, sirolimus MSH6 DHFR 1
treosulfan, fludarabine phosphate, tacrolimus, methotrexate, lapine t-lymphocyte immune globulin, peripheral blood stem cell transplantation, allogeneic bone marrow transplantation, quality-of-life assessment, echocardiography, multigated acquisition scan, bone marrow biopsy, bone marrow aspiration, biospecimen collection, x-ray imaging, computed tomography MSH6 DHFR 1
trilaciclib MSH6 CDK9 1
clofarabine MSH6 RRM2 7
gallium citrate MSH6 RRM2 7
gallium citrate ga 67 MSH6 RRM2 7
gallium nitrate MSH6 RRM2 7
gallium oxodotreotide MSH6 RRM2 7
gallium oxodotreotide ga-68 MSH6 RRM2 7
gemcitabine MSH6 RRM2 7
gemcitabine hydrochloride MSH6 RRM2 7
hydroxyurea MSH6 RRM2 7
methotrexate MSH6 DHFR 7
methotrexate sodium MSH6 DHFR 7
niraparib MSH6 PARP1 7
niraparib tosylate MSH6 PARP1 7
pemetrexed disodium MSH6 DHFR 7
pralatrexate MSH6 DHFR 7
rucaparib MSH6 PARP1 7
rucaparib camsylate MSH6 PARP1 7
talazoparib MSH6 PARP1 7
talazoparib tosylate MSH6 PARP1 7
unnamed compound MSH6 DHFR 7
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.